Compare Citius Pharmaceuticals Inc (CTXR) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs FuelCell Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while FuelCell Energy Inc trades at $21.9 (market cap $1.54B). The key difference: FuelCell Energy Inc is far larger — about 77× Citius Pharmaceuticals Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FCEL | |
|---|---|---|
Market Cap | $20.01M | $1.54B |
Sector | Health | Industrials |
52-Week High | $1.82 | $36.01 |
52-Week Low | $0.48 | $3.92 |
Enterprise Value | $16.23M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
FCEL trades at $22.16, up 11.75% in the past 24 hours, but remains in a bearish technical trend. The company continues to post significant losses, with a net income margin of -132.41% in 2025, despite recent revenue growth to $158.16M. Analyst sentiment is divided with a 45% buy and 45% hold consensus, and a price target of $20.75. Recent news highlights partnerships and volatility within the hydrogen sector.
The outlook is clouded by persistent unprofitability and negative cash flow from operations, posing substantial risk. Upside potential hinges on successful commercialization of technology and sector tailwinds, but the stock faces headwinds from execution challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
